AMRX vs ETON
AMRX: A diversified biopharmaceutical company providing a broad range of generic, branded, and specialty medicines alongside pharmaceutical distribution services. ETON: Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting ultra-rare genetic and metabolic disorders.
Side-by-side fundamentals
| Metric | AMRX | ETON | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $18.46 | $45.97 | |
| Market cap as of 2026-08-06 | $5.9B | $1.3B | |
| P/E as of 2026-08-06 | 48.27 | n/a | |
| PEG as of 2026-08-06 | 2.85 | n/a | |
| Net margin as of 2026-08-06 | +4.0% | -1.7% | AMRX higher |
| Gross margin as of 2026-08-06 | +38.7% | +54.8% | ETON higher |
| Operating margin as of 2026-08-06 | +14.3% | +2.4% | AMRX higher |
| ROE as of 2026-08-06 | -34.9% | -5.7% | ETON higher |
| ROA as of 2026-08-06 | +3.4% | -1.5% | AMRX higher |
| Debt / equity as of 2026-08-06 | 136.58 | 1.00 | ETON lower |
| Revenue growth (YoY) as of 2026-08-06 | +7.6% | +79.9% | ETON higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | +55.5% | ETON higher |
| Beta as of 2026-08-06 | 1.25 | 0.84 | |
| 1-year return as of 2026-08-05 close | +127.1% | +212.1% | ETON higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.